Analyst Viewpoint
High efficacy of monoclonal antibodies (mAbs) and rise in demand for organic treatments are propelling the anticancer drugs market size. Monoclonal antibodies are gaining traction as a favored method for the treatment of several types of cancer.
Governments in several countries are implementing various regulatory frameworks to support the R&D of anticancer medicines, which is offering lucrative opportunities to vendors in the global anticancer drugs industry. Vendors are conducting clinical trials to evaluate various drugs for the treatment of cancer. They are also acquiring other companies and investing in cutting-edge anticancer therapeutics to expand their customer base.
Cancer is a category of diseases characterized by abnormal cell formation with the potential to afflict or spread to other parts of the body. Carcinomas, sarcomas, lymphomas, and leukemia are all common types of tumors. Sarcomas begin in connective tissues such as muscle or bones. Sarcomas of the delicate tissues can begin in oily tissues. The management of cancer in patients requires the application of various treatments including hormone therapy, immunotherapy, targeted therapy, and other modalities.
Cancer is currently a leading cause of mortality worldwide, according to the World Health Organization (WHO), with 10 million annual deaths in 2020. Thus, high prevalence of cancer is fueling the anticancer drugs market value. The pharmaceutical industry is expanding rapidly, particularly in the field of anticancer medications and treatments. Rise in awareness about malignant diseases is boosting demand for anticancer drugs.
Significant costs associated with the R&D of new medicines and side effects associated with anticancer therapies are likely to limit the anticancer drugs market growth in the near future. Surge in healthcare expenditure in emerging countries and increase in investment in the R&D of new medicines are projected to offer lucrative anticancer drugs industry opportunities to vendors.
Major countries across the globe are implementing various regulatory frameworks to support the R&D of anticancer medications. In the U.S., the Food and Drug Administration has developed an educational initiative in association with the Oncology Center of Excellence (OCE) under the moniker Oncology Regulatory Expertise and Early Guidance (OREEG). It aims to aid early-stage oncology companies with anticancer drug research for quicker and more efficient development of relevant oncology drugs.
Monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to mimic the immune system's ability to fight off cancer cells and other harmful pathogens. Innovative small molecule inhibitors for melanoma represent an innovative approach to developing treatments for this type of cancer.
Monoclonal antibodies are designed to interact with specific targets. Targeted mAbs can cause tumor cell death by a variety of mechanisms. In October 2023, The Medicines and Healthcare Products Regulatory Agency (MHRA) authorized a new indication for Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults. This monoclonal antibody treatment is beneficial for patients with certain types of advanced or recurrent endometrial cancer. Thus, approval and launch of novel monoclonal antibody treatments is projected to augment the anticancer drugs market progress in the next few years.
According to the latest anticancer drugs market analysis, monoclonal antibodies are applied in emerging immunotherapy drugs for lung cancer. Some monoclonal antibodies label cancer cells so that the immune system can better recognize and eliminate them. Rituximab, for example, attaches to a protein called CD20 on B cells and certain cancer cells, prompting the immune system to destroy them. This technique allows doctors to target tumors without harming healthy cells. It usually has fewer adverse effects than other cancer therapies and is very effective in the battle against cancer.
Integrative oncology research helps to determine whether complementary therapies, including herbal anticancer drugs, are safe and effective to be combined with traditional cancer treatments. For more than a half-century, natural compounds with robust chemical diversity have been widely researched for their anticancer properties. Microbes and plants from terrestrial and marine settings are the primary suppliers of these chemicals. Microorganisms are a significant source of antitumor natural compounds. Several of these products were first identified as anticancer antibiotics.
Plant alkaloids, taxoids, and podophyllotoxins are classes of compounds derived from plants that have shown significant therapeutic potential, particularly in the field of cancer treatment. Taxol (paclitaxel), for example, is a mesothelioma chemotherapy medication derived from the bark of the yew tree. Rapidly developing resistance to chemotherapeutic treatments has necessitated the development of innovative medications for cancer therapy. The high toxicity and unfavorable side effects of traditional medicines are prompting the development of organic therapeutic substances. According to a March 2020 report by the American Chemical Society and the American Society of Pharmacognosy, natural products were responsible for nearly 25% of all newly authorized anticancer medications between 1981 and 2019. Hence, R&D of organic treatments is fueling the anticancer drugs market revenue.
According to the latest anticancer drugs market forecast, North America is projected to hold largest share from 2023 to 2031. Rise in prevalence of cancer and presence of modern healthcare infrastructure are fueling the market dynamics of the region. Surge in healthcare expenditure and easy availability of pharmaceuticals is also boosting the anticancer drugs industry trajectory in North America.
Major players are investing in the R&D of new products to expand their product portfolio and increase their anticancer drugs market share. Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bayer AG, Merck & Co. Inc., and Celgene Corporation are key players operating in this market.
Each of these players has been profiled in the anticancer drugs market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 140.2 Bn |
| Market Forecast Value in 2031 | US$ 303.1 Bn |
| Growth Rate (CAGR) | 9.1% |
| Forecast Period | 2023 to 2031 |
| Historical Data Available for | 2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 140.2 Bn in 2022
It is likely to grow at a CAGR of 9.1% from 2023 to 2031
High efficacy of monoclonal antibodies and rise in demand for organic treatments
North America held largest share in 2022
Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bayer AG, Merck & Co. Inc., and Celgene Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anticancer Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anticancer Drugs Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Anticancer Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2023–2031
6.3.1. Cytotoxic Drugs
6.3.1.1. Alkylating Agents
6.3.1.2. Antimetabolites
6.3.1.3. Others
6.3.2. Targeted Drugs
6.3.2.1. Monoclonal Antibodies
6.3.2.2. Tyrosine Kinase Inhibitors
6.3.2.3. Others
6.3.3. Hormonal Drugs
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Anticancer Drugs Market Analysis and Forecast, by Therapy Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Therapy Type, 2023–2031
7.3.1. Chemotherapy
7.3.2. Targeted Therapy
7.3.3. Immunotherapy
7.3.4. Others
7.4. Market Attractiveness Analysis, by Therapy Type
8. Global Anticancer Drugs Market Analysis and Forecast, by Cancer Type
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Cancer Type, 2023–2031
8.3.1. Lung Cancer
8.3.2. Breast Cancer
8.3.3. Leukemia
8.3.4. Colorectal Cancer
8.3.5. Others
8.4. Market Attractiveness Analysis, by Therapy Type
9. Global Anticancer Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Anticancer Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2023–2031
10.3.1. Cytotoxic Drugs
10.3.1.1. Alkylating Agents
10.3.1.2. Antimetabolites
10.3.1.3. Others
10.3.2. Targeted Drugs
10.3.2.1. Monoclonal Antibodies
10.3.2.2. Tyrosine Kinase Inhibitors
10.3.2.3. Others
10.3.3. Hormonal Drugs
10.4. Market Value Forecast, by Therapy Type, 2023–2031
10.4.1. Chemotherapy
10.4.2. Targeted Therapy
10.4.3. Immunotherapy
10.4.4. Others
10.5. Market Value Forecast, by Cancer Type, 2023–2031
10.5.1. Lung Cancer
10.5.2. Breast Cancer
10.5.3. Leukemia
10.5.4. Colorectal Cancer
10.5.5. Others
10.6. Market Value Forecast, by Country, 2023–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Therapy Type
10.7.3. By Cancer Type
10.7.4. By Country
11. Europe Anticancer Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2023–2031
11.3.1. Cytotoxic Drugs
11.3.1.1. Alkylating Agents
11.3.1.2. Antimetabolites
11.3.1.3. Others
11.3.2. Targeted Drugs
11.3.2.1. Monoclonal Antibodies
11.3.2.2. Tyrosine Kinase Inhibitors
11.3.2.3. Others
11.3.3. Hormonal Drugs
11.4. Market Value Forecast, by Therapy Type, 2023–2031
11.4.1. Chemotherapy
11.4.2. Targeted Therapy
11.4.3. Immunotherapy
11.4.4. Others
11.5. Market Value Forecast, by Cancer Type, 2023–2031
11.5.1. Lung Cancer
11.5.2. Breast Cancer
11.5.3. Leukemia
11.5.4. Colorectal Cancer
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2023–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Therapy Type
11.7.3. By Cancer Type
11.7.4. By Country/Sub-region
12. Asia Pacific Anticancer Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2023–2031
12.3.1. Cytotoxic Drugs
12.3.1.1. Alkylating Agents
12.3.1.2. Antimetabolites
12.3.1.3. Others
12.3.2. Targeted Drugs
12.3.2.1. Monoclonal Antibodies
12.3.2.2. Tyrosine Kinase Inhibitors
12.3.2.3. Others
12.3.3. Hormonal Drugs
12.4. Market Value Forecast, by Therapy Type, 2023–2031
12.4.1. Chemotherapy
12.4.2. Targeted Therapy
12.4.3. Immunotherapy
12.4.4. Others
12.5. Market Value Forecast, by Cancer Type, 2023–2031
12.5.1. Lung Cancer
12.5.2. Breast Cancer
12.5.3. Leukemia
12.5.4. Colorectal Cancer
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2023–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Therapy Type
12.7.3. By Cancer Type
12.7.4. By Country/Sub-region
13. Latin America Anticancer Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2023–2031
13.3.1. Cytotoxic Drugs
13.3.1.1. Alkylating Agents
13.3.1.2. Antimetabolites
13.3.1.3. Others
13.3.2. Targeted Drugs
13.3.2.1. Monoclonal Antibodies
13.3.2.2. Tyrosine Kinase Inhibitors
13.3.2.3. Others
13.3.3. Hormonal Drugs
13.4. Market Value Forecast, by Therapy Type, 2023–2031
13.4.1. Chemotherapy
13.4.2. Targeted Therapy
13.4.3. Immunotherapy
13.4.4. Others
13.5. Market Value Forecast, by Cancer Type, 2023–2031
13.5.1. Lung Cancer
13.5.2. Breast Cancer
13.5.3. Leukemia
13.5.4. Colorectal Cancer
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2023–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Therapy Type
13.7.3. By Cancer Type
13.7.4. By Country/Sub-region
14. Middle East & Africa Anticancer Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Type, 2023–2031
14.3.1. Cytotoxic Drugs
14.3.1.1. Alkylating Agents
14.3.1.2. Antimetabolites
14.3.1.3. Others
14.3.2. Targeted Drugs
14.3.2.1. Monoclonal Antibodies
14.3.2.2. Tyrosine Kinase Inhibitors
14.3.2.3. Others
14.3.3. Hormonal Drugs
14.4. Market Value Forecast, by Therapy Type, 2023–2031
14.4.1. Chemotherapy
14.4.2. Targeted Therapy
14.4.3. Immunotherapy
14.4.4. Others
14.5. Market Value Forecast, by Cancer Type, 2023–2031
14.5.1. Lung Cancer
14.5.2. Breast Cancer
14.5.3. Leukemia
14.5.4. Colorectal Cancer
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2023–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Therapy Type
14.7.3. By Cancer Type
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Eli Lilly and Company
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Pfizer Inc
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Bayer AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. AstraZeneca
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Takeda Pharmaceutical Company Limited
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Merck & Co., Inc
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. CELGENE CORPORATION
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Amgen Inc
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031
Table 02: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031
Table 03: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031
Table 04: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Region, 2023–2031
Table 05: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country, 2023–2031
Table 06: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031
Table 07: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031
Table 08: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031
Table 09: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 10: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031
Table 11: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031
Table 12: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031
Table 13: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031
Table 15: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031
Table 16: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031
Table 17: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 18: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031
Table 19: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031
Table 20: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031
Table 21: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 22: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031
Table 23: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031
Table 24: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031
List of Figures
Figure 01: Global Anticancer Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031
Figure 02: Global Anticancer Drugs Market Revenue (US$ Mn), by Drug Type, 2022
Figure 03: Global Anticancer Drugs Market Value Share, by Drug Type, 2022
Figure 04: Global Anticancer Drugs Market Revenue (US$ Mn), by Therapy Type, 2022
Figure 05: Global Anticancer Drugs Market Value Share, by Therapy Type, 2022
Figure 06: Global Anticancer Drugs Market Revenue (US$ Mn), by Cancer Type, 2022
Figure 07: Global Anticancer Drugs Market Value Share, by Cancer Type, 2022
Figure 08: Global Anticancer Drugs Market Value Share, by Region, 2022
Figure 09: Global Anticancer Drugs Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
Figure 11: Global Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 12: Global Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
Figure 13: Global Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031
Figure 14: Global Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
Figure 15: Global Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031
Figure 16: Global Anticancer Drugs Market Value Share Analysis, by Region, 2023 and 2031
Figure 17: Global Anticancer Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 19: North America Anticancer Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Anticancer Drugs Market Value Share Analysis, by Country, 2023 and 2031
Figure 21: North America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
Figure 22: North America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
Figure 23: North America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
Figure 24: North America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 25: North America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031
Figure 26:North America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 27: Europe Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 28: Europe Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 30: Europe Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
Figure 31: Europe Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
Figure 32: Europe Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
Figure 33: Europe Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 34: Europe Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031
Figure 35: Europe Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 36: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 37: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 39: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
Figure 40: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
Figure 41: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
Figure 42: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 43: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031
Figure 44: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 45: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 46: Latin America Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 48: Latin America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
Figure 49: Latin America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
Figure 50: Latin America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
Figure 51: Latin America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 52: Latin America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031
Figure 53: Latin America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 54: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 55: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 57: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031
Figure 58: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031
Figure 59: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031
Figure 60: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 61: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031
Figure 62: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Anticancer Drugs Market
